Tasigna Lawsuit Information – Related Injury Claims

Tasigna was approved by the U.S. Food and Drug Administration in 2007 for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The medication belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which block a protein called Bcr-ABl to stop the growth of cancer cells.

On the Tasigna website, there is a warning that the drug can cause a life-threatening heart problem called QTc prolongation. If you or a loved one who has experienced the side effects with Tasigna, then you can browse this useful reference: “Tasigna Lawyer | Tasigna Lawsuit”.

But lots of suits filed by patients waive the medication of inducing”acute, rapid and irreversible atherosclerosis-related ailments.”Atherosclerosis is an accumulation of plaque from the walls of a molecule which could make a congestion of blood.From the latest litigation , a Washington man represented by New Enforcement law company Bernstein Liebhard LLP, said that the patient was carrying a second Novartis medicine, Gleevec, to take care of his chronic myeloid leukemia.

Nevertheless, the individual’s oncologist switched him Tasigna even though his leukemia in remission.  Subsequent to the drug was changed the affected person, 66, suffered by the stroke, according to a statement by the law business.

Image Source: https://media.oncologynurseadvisor.com/images/2017/07/12/pediatricg622282914_1257950.jpg?format=jpg&zoom=1&quality=70&anchor=middlecenter&width=320&mode=pad

The individual had no history of atherosclerosis-related ailments.  The suit claims that the Novartis drug”caused him to grow rapidly advancing atherosclerosis within his carotid arteries “Since Tasigna’s regulatory approval,” Bernstein Liebhard LLP said that there has been a few published studies which indicated: “patients medicated with Tasigna maybe more inclined to come up with arteriosclerosis-related condition.”

The risk of Tasigna atherosclerosis was detected in clinical studies published in 2011, and a Tasigna atherosclerosis warning was added to the drug’s warning label in 2013. However, many Americans are unaware of the risk of Tasigna atherosclerosis and continue to consent to using this powerful cancer drug without full knowledge of the risks.

Rapid onset atherosclerosis from Tasigna can result in tissue death and the need for limb amputation, as well as other cardiovascular problems, peripheral arterial disease, and death. Read for full Tasigna atherosclerosis warning information.